title: Pharmacokinetics of dolutegravir in a premature neonate after HIV treatment intensification during pregnancy.
abstract: We describe the pharmacokinetics of dolutegravir (DTG) in a premature neonate after maternal intensification of an antiretroviral (ARV) regimen by adding DTG. During the last 2 weeks of pregnancy, the ARV was tenofovir-emtricitabine, atazanavir-ritonavir, and DTG (50 mg once daily). From the interaction between atazanavir and DTG via CYP3A4 and UGT1A1 and placental efflux transporter inhibition and considering the infant's probable enzymatic immaturity, the DTG elimination half-life was estimated to be 4-fold longer in neonates than in adults.
authors.affiliation: AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France.
authors.forename: J B
authors.initials: JB
authors.lastname: Pain
authors.affiliation: AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France minh.le@bch.aphp.fr.
authors.forename: M P
authors.initials: MP
authors.lastname: Lê
authors.affiliation: AP-HP, General Pediatrics, Robert Debré Hospital, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Caseris
authors.affiliation: AP-HP, Virology Department, Tenon Hospital, Paris, France AP-HP, UPMC Université Paris 06, UMRS CR7, Inserm U1135, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Amiel
authors.affiliation: AP-HP, Infectious Diseases Unit, Tenon Hospital, Paris, France.
authors.forename: L
authors.initials: L
authors.lastname: Lassel
authors.affiliation: AP-HP, Virology Department, Bichat Hospital, Paris, France IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and UMR 1137, INSERM, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Charpentier
authors.affiliation: AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Desnoyer
authors.affiliation: AP-HP, Neonatology Department, Robert Debré Hospital, Paris, France.
authors.forename: C
authors.initials: C
authors.lastname: Farnoux
authors.affiliation: AP-HP, UPMC Université Paris 06, UMRS CR7, Inserm U1135, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Pialoux
authors.affiliation: AP-HP, Virology Department, Bichat Hospital, Paris, France IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and UMR 1137, INSERM, Paris, France.
authors.forename: D
authors.initials: D
authors.lastname: Descamps
authors.affiliation: AP-HP, Clinical Pharmacology Department, Bichat Hospital, Paris, France IAME, UMR 1137, Université Paris Diderot, Sorbonne Paris Cité and UMR 1137, INSERM, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Peytavin
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D000069446:Atazanavir Sulfate / Q000493:pharmacokinetics / Q000627:therapeutic use; D051544:Cytochrome P-450 CYP3A / Q000378:metabolism; D000068679:Emtricitabine / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D014453:Glucuronosyltransferase / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism; D006575:Heterocyclic Compounds, 3-Ring / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010078:Oxazines; D010879:Piperazines; D011247:Pregnancy; D011728:Pyridones; D019438:Ritonavir / Q000493:pharmacokinetics / Q000627:therapeutic use; D000068698:Tenofovir / Q000493:pharmacokinetics / Q000627:therapeutic use; D000099148:UGT1A1 Enzyme; D000099226:Dolutegravir
chemical_list: D019380:Anti-HIV Agents; D000069446:Atazanavir Sulfate; D051544:Cytochrome P-450 CYP3A; D000068679:Emtricitabine; D014453:Glucuronosyltransferase; D006575:Heterocyclic Compounds, 3-Ring; D010078:Oxazines; D010879:Piperazines; D011728:Pyridones; D019438:Ritonavir; D000068698:Tenofovir; D000099148:UGT1A1 Enzyme; D000099226:Dolutegravir
references.citation: Biomed Chromatogr. 2007 Oct;21(10):1095-104
references.pmid: 17582235
references.citation: J Pharm Sci. 2009 Jul;98(7):2317-35
references.pmid: 19067393
references.citation: Br J Clin Pharmacol. 2011 Jul;72(1):103-8
references.pmid: 21342217
references.citation: Drug Metab Dispos. 2011 May;39(5):912-9
references.pmid: 21266593
references.citation: Curr HIV Res. 2009 Nov;7(6):620-5
references.pmid: 19929798